-
ImmuneOnco Biopharmaceuticals Launches IPO to Raise HKD 319 Million on Hong Kong Stock Exchange
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) is poised to raise HKD 319 million (USD 40.7 million) through an initial public offering (IPO) on the Hong Kong Stock Exchange. The biotech company will offer 17,147,200 shares at a price point of HKD 18.6 per share, with ImmuneOnco set to list…
-
Dizal Pharmaceutical’s Sunvozertinib Approved by China’s NMPA for NSCLC Treatment
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its next-generation epidermal growth factor receptor (EGFR) inhibitor, sunvozertinib. This novel targeted therapy is now approved for the treatment of locally advanced or metastatic non-small cell lung…
-
Hinova Pharmaceuticals’ HP518 for mCRPC Accepted for Review by China’s NMPA
•
Chengdu-based biotech company Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that the National Medical Products Administration (NMPA) has accepted its clinical filing for HP518, a Category 1 chemical drug intended to treat metastatic castration-resistant prostate cancer (mCRPC). HP518: A Promising PROTAC Drug for Prostate CancerHP518 is an androgen receptor (AR)…
-
Labway Clinical Laboratory Partners with 10x Genomics for Precision Medicine Advancements
•
Shanghai Labway Clinical Laboratory Co., Ltd., a leading provider of medical laboratory and pathological diagnostic services, has announced a strategic collaboration with US-based firm 10x Genomics. The partnership focuses on advancing the fields of single-cell analysis, spatial genomics, and precision medicine. Labway’s Comprehensive Technological PlatformsLabway, which already possesses capabilities in…
-
Akeso Biopharma’s Ebdarokimab (AK101) NDA Accepted for Review by China’s CDE
•
China-based Akeso Biopharma (HKG: 9926) has announced that the New Drug Application (NDA) for its monoclonal antibody ebdarokimab (AK101), which targets IL-12 and IL-23, has been accepted for review by the Center for Drug Evaluation (CDE) in China. The drug is intended for the treatment of moderate to severe plaque…
-
Beijing Drafts Regulations for Internet Diagnosis and Treatment, Prohibits AI Prescriptions
•
The Beijing Municipal Health Commission has released the “Implementation Measures for Internet Diagnosis and Treatment Supervision in Beijing (Trial)(draft proposal)” and is soliciting public feedback from August 17 to September 16, 2023. This document outlines the supervision of online diagnosis and treatment activities by medical institutions in Beijing, aligning with…
-
Innovent Biologics Reports 20.6% YOY Revenue Growth in H1 2023 Financials
•
China-based Innovent Biologics Inc., (HKG: 1801) has released its financial results for the first half of 2023, reporting a total revenue of RMB 2.7 billion (USD 374 million), marking a 20.6% year-on-year (YOY) increase. The actual product sales contributed RMB 2.458 billion (USD 340 million) to the total, also up…
-
Eli Lilly’s Retevmo Meets Primary Endpoint in Phase III Trial for RET-mutant Medullary Thyroid Cancer
•
Eli Lilly (NYSE: LLY) has announced that its Phase III trial for the RET kinase inhibitor Retevmo (selpercatinib) has successfully met its primary endpoint in patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC). The trial demonstrated a significant improvement in progression-free survival (PFS) compared to cabozantinib or vandetanib,…
